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Abstract:  Probiotics are live microorganisms that promote health benefits upon 
consumption, while prebiotics are nondigestible food ingredients that selectively stimulate 
the growth of beneficial microorganisms in the gastrointestinal tract. Probiotics and/or 
prebiotics could be used as alternative supplements to exert health benefits, including 
cholesterol-lowering effects on humans. Past in vivo studies showed that the administration 
of probiotics and/or prebiotics are effective in improving lipid profiles, including the 
reduction of serum/plasma total cholesterol, LDL-cholesterol and triglycerides or 
increment of HDL-cholesterol. However, other past studies have also shown that probiotics 
and prebiotics had insignificant effects on lipid profiles, disputing the hypocholesterolemic 
claim. Additionally, little information is available on the effective dosage of probiotics and 
prebiotics needed to exert hypocholesterolemic effects. Probiotics and prebiotics have been 
suggested to reduce cholesterol via various mechanisms. However, more clinical evidence 
is needed to strengthen these proposals. Safety issues regarding probiotics and/or 
prebiotics have also been raised despite their long history of safe use. Although probiotic-
mediated infections are rare, several cases of systemic infections caused by probiotics have 
been reported and the issue of antibiotic resistance has sparked much debate. Prebiotics, 
classified as food ingredients, are generally considered safe, but overconsumption could 
cause intestinal discomfort. Conscientious prescription of probiotics and/or prebiotics is 
crucial, especially when administering to specific high risk groups such as infants, the 
elderly and the immuno-compromised. 
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1. Introduction 
The WHO has predicted that by 2030, cardiovascular diseases will remain the leading causes of 
death, affecting approximately 23.6 million people around the World [1]. It was reported that 
hypercholesterolemia contributed to 45% of heart attacks in Western Europe and 35% of heart attacks 
in Central and Eastern Europe from 1999 to 2003 [2]. The risk of heart attack is three times higher in 
those with hypercholesterolemia, compared to those who have normal blood lipid profiles. The WHO 
delineated that unhealthy diets such as those high in fat, salt and free sugar, and low in complex 
carbohydrates, fruits and vegetables, lead to increased risk of cardiovascular diseases [3]. 
People affected with hypercholesterolemia may avert the use of cholesterol-lowering drugs by 
practising dietary control or supplementation of probiotics and/or prebiotics. Probiotics are defined as 
‘living microbial supplements that beneficially affect the host animals by improving its intestinal 
microbial balances’ [4]. Prebiotics are ‘indigestible fermented food substrates that selectively 
stimulate the growth, composition and activity of microflora in gastrointestinal tract and thus improve 
hosts’ health and well-being’ [5]. When probiotics and prebiotics are used in combination, they are 
known as ‘synbiotics’. The use of probiotics and prebiotics has only acquired scientific recognition in 
recent years although their applications as functional foods have been well-established throughout 
generations. In the interest of their promising effects on health and well being, probiotics and 
prebiotics have become increasingly recognized as supplements for human consumption.  
In addition to improving gut health, probiotics have also been documented to exert other health-
promoting effects such as strengthening of the immune system [6], antihypertensive effects [7], 
prevention of cancer [8], antioxidative effects [9], reduction of dermatitis symptoms [10], facilitation 
of mineral absorption [11], amelioration of arthritis [12], reduction of allergic symptoms [13] and 
improvement of vulvovaginal candidiasis in women [14]. Probiotics have also been studied for their 
cholesterol-lowering effects [15]. 
Fructooligosaccharides, inulin, oligofructose, lactulose, and galactooligosaccharides have been 
identified as prebiotics due to characteristics such as resistance to gastric acidity, hydrolysis by 
mammalian enzymes and are fermented by gastrointestinal microflora to further selectively stimulate 
the growth and/or activity of beneficial intestinal bacteria. New compounds with gut resistant 
properties and selective fermentability by intestinal microorganisms are continuingly being identified 
and developed as prebiotics [16]. These include oligosaccharides (isomaltooligosaccharides, 
lactosucrose, xylooligosaccharides and glucooligosaccharides), sugar alcohols and polysaccharides 
(starch, resistant starch and modified starch) [17]. Generally, prebiotics offer promising health benefits 
such as improving gastrointestinal microflora by selectively promoting the growth of probiotics and/or 
inhibition of pathogenic microorganisms [18], stimulation of the immune system [19], cancer 
prevention [20], stimulation of mineral absorption and bone stability [21] and treatment of irritable 
bowel-associated diarrhoeas [22]. Prebiotics are utilized by the intestinal microbial population to Int. J. Mol. Sci. 2010, 11               
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produce short-chain fatty acids which may lead to the reduced incidence of gastrointestinal disease 
[23], cancers [24] and cardiovascular diseases [25]; and improvement of lipid profiles [26]. 
Studies examining the efficacy of probiotics in reducing cholesterol often do not sufficiently 
address the mechanisms by which probiotics modulate hypocholesterolemic effects and the optimum 
dose, frequency, and duration of treatment for different probiotic strains. Several mechanisms have 
been hypothesized, which include enzymatic deconjugation of bile acids by bile-salt hydrolase of 
probiotics [27], assimilation of cholesterol by probiotics [28], co-precipitation of cholesterol with 
deconjugated bile [29], cholesterol binding to cell walls of probiotics [30], incorporation of cholesterol 
into the cellular membranes of probiotics during growth [31], conversion of cholesterol into 
coprostanol [32] and production of short-chain fatty acids upon fermentation by probiotics in the 
presence of prebiotics [33].  
Probiotics are generally known to be nonpathogenic but they could be infectious, especially in 
debilitated and immuno-compromised populations [34]. Some species of Lactobacillus, 
Bifidobacterium, Leuconostoc, Enterococcus and Pediococcus have been isolated from infection sites 
[35]. Strains of probiotics have also been found to exhibit antibiotic resistance and have raised 
concerns about horizontal resistant gene transfer to the host and the pool of gastrointestinal pathogenic 
microflora [36]. Considering
  this, the safety
  verification of probiotics used industrially and
 
commercially is of utmost importance. 
2. Hypocholesterolemic Potential: In Vivo Evidence and Controversies 
The use of animals and humans models to evaluate the effects of probiotics and prebiotics on serum 
cholesterol levels has been emphasized over the years. Human studies have shown promising evidence 
that well-established probiotics and/or prebiotics possess hypocholesterolemic effects, while new 
strains of probiotics or new type of prebiotics have been evaluated in animal models for their potential 
hypocholesterolemic effects. Many studies have used rats [37,38], mice [39], hamsters [40], guinea 
pigs [41] and pigs [42] as models due to their similarities with humans in terms of cholesterol and bile 
acid metabolism, plasma lipoprotein distribution, and regulation of hepatic cholesterol enzymes [43]. 
These animals also share an almost similar digestive anatomy and physiology, nutrient requirements, 
bioavailability and absorption, and metabolic processes with humans, making them useful 
experimental models for research applications [42]. Hence, the positive hypocholesterolemic effects 
shown in animal studies suggest a similar potential in humans. Human trial results that paralleled those 
obtained from animal studies have further attested to the transferability and reliability of results 
obtained in selected animal models.  
In a study evaluating the effect of L. plantarum PH04 (isolated from infant feces) on cholesterol, 
Nguyen et al. [44] administered L. plantarum (4  10
8 CFU/mL dose per mouse in daily) to twelve 
male hypercholesterolemic mice for 14 days. The authors found a significant (P < 0.05) reduction of 
total serum cholesterol (reduced by 7%) and triglycerides (reduced by 10%) compared to the control. 
In another study, Abd El-Gawad et al. [45] conducted a randomized, placebo-controlled and parallel 
designed study to assess the efficiency of buffalo milk-yogurts (fortified with Bifidobacterium longum 
Bb-46) in exerting a cholesterol-lowering effect. In the study, the authors fed forty-eight male albino 
hypercholesterolemic rats (average weight 80-100 g) with 50 g of yogurt [contained 0.07% (w/v) Int. J. Mol. Sci. 2010, 11               
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Bifidobacterium longum Bb-46] daily for 35 days. The administration of B. longum Bb-46-fermented 
buffalo milk-yogurt significantly reduced concentration of total cholesterol by 50.3%, LDL-cholesterol 
by 56.3% and triglycerides by 51.2% compared to the control (P < 0.05). In another study, Fukushima 
et al. [46] found that hypercholesterolemic male Fischer 344/Jcl rats (8 week old) fed with 30 g/kg of 
L. acidophilus-fermented rice bran significantly showed an improved lipid profile compared to the 
control (without L. acidophilus). In this 4-week study, the authors reported a significant (P < 0.05) 
reduction in serum total cholesterol and liver cholesterol of 21.3% and 22.9%, respectively compared 
to the control. The hypocholesterolemic potential of probiotics has also been evaluated using human 
subjects. Anderson et al. [47] explored the effect of fermented milk containing L. acidophilus L1 on 
serum cholesterol in hypercholesterolemic humans. This randomized, double-blind, placebo-controlled 
and crossover 10-week study was designed for forty-eight volunteers whose serum cholesterol values 
ranged from 5.40 mmol/L to 8.32 mmol/L. Daily consumption of 200 g of yogurt containing L. 
acidophilus L1 after each dinner contributed to a significant (P < 0.05) reduction in serum cholesterol 
concentration (-2.4%) compared to the placebo group. In another study, Xiao et al. [48] evaluated the 
effects of a low-fat yogurt containing 10
8 CFU/g of B. longum BL1 on lipid profiles of thirty-two 
subjects (baseline serum total cholesterol 220-280 mg/dL, body weight 55.4-81.8 kg, aged 28-60 years 
old). Results from this randomized, single-blind, placebo-controlled and parallel study showed a 
significant (P < 0.05) decline in serum total cholesterol, LDL-cholesterol and triglycerides after   
4-weeks. The authors also observed a 14.5% increase in HDL-cholesterol when comparing to the 
control (yoghurt without B. longum BL1; P < 0.05).  
While the hypocholesterolemic effect of probiotics has been well-documented, prebiotics have also 
gained increasing attention in cholesterol studies, due to their role in promoting the growth of 
probiotics. Causey et al. [49] conducted a randomized, double-blind and crossover study using 
hypercholesterolemic subjects to assess the effects of inulin from chicory root on blood cholesterol 
level. This study involved twelve men that were randomly assigned to two groups, namely the control 
group (consumed one pint of vanilla ice-cream without inulin) and the inulin group (consumed one 
pint of vanilla ice-cream containing 20 g of inulin). The 3-week study found that daily intake of 20 g 
of inulin significantly (P  < 0.05) reduced serum triglycerides. Similarly, another double-blind, 
randomized and placebo-controlled crossover study involving eight healthy volunteers with a daily 
consumption of 10 g of inulin for three weeks has also reached the same conclusion [50]. Plasma 
triacylglycerol concentrations was significantly (P < 0.05) lower compared to the placebo [50]. In 
another study, Brighenti et al. [51] used a randomized, double-blind, placebo-controlled and parallel 
design trial involving twelve healthy male volunteers to study the effect of prebiotic on lipid profiles. 
In this 12-week trial, the authors found that the daily consumption of 50 g of a rice-based ready-to-eat 
cereal containing 18% inulin significantly (P  < 0.05) reduced plasma total cholesterol and 
triacylglycerols by 7.9% (±5.4) and 21.2% (±7.8), respectively compared to the control. Similarly, 
Mortensen et al. [52] found that forty male mice fed with a purified diet with 10% of long-chained 
fructan for 16 weeks showed that the fructan significantly reduced blood cholesterol by 29.7%   
(P < 0.001), LDL-cholesterol concentration by 25.9% (P < 0.01), IDL-cholesterol level by 39.4%  
(P < 0.001) and VLDL-cholesterol concentration by 37.3% (P < 0.05) compared to the control group.  
Other indigestible and fermentable compounds such as germinated barley, oligodextrans, gluconic 
acid, lactose, glutamine, hemicellulose-rich substrates, resistant starch and its derivatives, lactoferrin-Int. J. Mol. Sci. 2010, 11               
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derived peptide, and N-acetylchitooligosaccharides [53] have also been identified to exert prebiotic 
potentials with hypocholesterolemic effects. In a study evaluating the cholesterol-lowering effect of 
resistant starch, Fernandez et al. [43] administered 10 g/100 g of resistant starch (obtained from the 
Meer Corporation) to male Hartley guinea pigs (body weight of 300-400 g) for four weeks. This 
randomized, placebo-controlled and parallel designed study used sixteen male guinea pigs and the 
results showed that the resistant starch significantly reduced (P < 0.01) plasma cholesterol by 27.4% 
and LDL-cholesterol concentration by 28.0% compared to the control group. In another randomized, 
placebo-controlled and parallel designed study, Wang et al. [54] found that ten male 
hypercholesterolemic Wistar rats (7-week-old; mean body weight of 210 ± 20 g) fed with a starch from 
Chinese yam (Dioscorea opposita cv. Anguo) for eight weeks showed a significantly lower plasma 
total cholesterol, LDL-cholesterol and triglyceride (P < 0.05) than the control (32.8%, 27.5% and 
46.2% lower, respectively).  Favier  et al. [55] evaluated the hypocholesterolemic effects of   
β- cyclodextrin in a randomized, placebo-controlled and parallel design trial involving ten male Wistar 
rats (mean body weight of 150 g). In this 21-day trial, the authors found that daily consumption of  
25 g/kg of β-cyclodextrin significantly (P < 0.05) reduced plasma cholesterol and triacylglycerols by 
25.9% and 35.0%, respectively, compared to the control group. 
Studies have presented evidence of independent hypocholesterolemic effects of probiotics and 
prebiotics, leading to subsequent evaluations on synbiotics. The administration of a synbiotic product 
(containing L. acidophilus ATCC 4962, fructooligosaccharides, mannitol and inulin) to twenty-four 
hypercholesterolemic male pigs yielded promising hypocholesterolemic effects [56]. The authors 
reported a significant reduction of plasma total cholesterol (P < 0.001), triacylglycerol (P < 0.001) and  
LDL-cholesterol (P < 0.045) in pigs consuming the synbiotic diet for eight weeks compared to the 
control. Kieβling  et al. [57] evaluated the hypocholesterolemic effect of a synbiotic yoghurt 
(containing L. acidophilus 145, B. longum 913 and oligofructose) in a randomized, placebo-controlled 
and crossover study involving twenty-nine women. The authors found that the daily consumption of 
300 g synbiotic yoghurt over 21 weeks significantly increased (P < 0.002) serum HDL-cholesterol by 
0.3 mmol/L, leading to an improved ratio of LDL/HDL. In another study, Schaafsma et al.  [58] 
conducted a randomized, placebo-controlled, double blind and crossover designed study involving 
thirty volunteers (aged 33-64 years old; body weight 66.5-98.0 kg) with mean total cholesterol of  
5.23 ± 1.03 mmol/L and LDL-cholesterol of 3.42 ± 0.94 mmol/L. In this study, the authors observed 
that daily consumption of 375 mL synbiotic milk [containing of 10
7-10
8 CFU/g of Lactobacillus 
acidophilus and 2.5% (g/100 g) of fructooligosaccharides] resulted in a significant decline in total 
cholesterol (P < 0.001), LDL-cholesterol (P < 0.005) and LDL/HDL ratio (P < 0.05) of 4.4%, 5.4% 
and 5.3% respectively. 
Although many studies have demonstrated convincing cholesterol-lowering effects of probiotics in 
both animals and humans, controversial results have surfaced. A study by Hatakka et al. [59] refuted 
the purported hypocholesterolemic effect of probiotics, and reported that the administration of L. 
rhamnosus LC705 (10
10 CFU/g per capsule; two capsules daily) did not influence blood lipid profiles 
in thirty-eight men with mean cholesterol levels of 6.2 mmol/L after a 4-week treatment period. In 
another study involving forty-six volunteers (aged 30-75 years old), Simons et al. [60] found that the 
consumption of Lactobacillus fermentum, (2  10
9 CFU per capsule; four capsules daily) did not 
contribute to any lipid profile changes after 10 weeks. Lewis and Burmeister [61] conducted a Int. J. Mol. Sci. 2010, 11               
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randomized, placebo-controlled double blind and crossover designed study to determine the effect of 
Lactobacillus acidophilus on human lipid profiles. In the study, eighty volunteers (aged 20-65 years 
old; baseline total cholesterol of > 5.0 mmol/L; mean Body Mass Index of 27.8 kg/m
2) consumed two 
capsules containing freeze-dried L. acidophilus (3  10
10 CFU/2 capsules) three times daily for six 
weeks, and crossed over for another six weeks after a 6-week washout period. The authors found that  
L. acidophilus capsules did not significantly change plasma total cholesterol, LDL-cholesterol,   
HDL-cholesterol and triglycerides of the subjects. Similar controversies were also raised from studies 
evaluating the hypocholesterolemic properties of prebiotics and also when probiotics and prebiotics 
were used together (synbiotic) (Table 1).  
Table 1. Controversial hypocholesterolemic effects of prebiotic and synbiotic. 
Compound(s) 
Experimental 
design 
Subjects 
Dose; duration of 
the study 
Effects  Ref. 
Inulin  Randomized, 
placebo-controlled, 
double-blind & 
crossover. 
8 volunteers.   3-4 g/100 of inulin & 
wheat fiber daily for 12 
weeks. 
No significant 
improvement 
in lipid 
profiles. 
[62] 
Fructooligo-
saccharides 
(FOS) 
Randomized, 
placebo-controlled, 
double-blind & 
crossover. 
10 diabetic patients (6 
men and 4 women); 
with plasma TC of 
4.85-5.58 mmol/L. 
20 g FOS/day for  
4 weeks. 
No significant 
improvement 
in lipid 
profiles. 
[63] 
Inulin  Randomized, 
placebo-controlled, 
double-blind & 
crossover designed 
study; with 2 six-
week treatment 
periods, separated 
by a six-week 
washout period. 
25 subjects; with 
baseline LDL-C 
ranging from 3.36-
5.17 mmol/L. 
45 g chocolate bar 
(containing of 18 g of 
inulin) daily during 
treatment period. 
No significant 
improvement 
in lipid 
profiles. 
[64] 
L. acidophilus 
& B. longum 
& fructooligo-
saccharides 
(FOS) 
Randomized, 
single-blind, 
placebo-controlled 
& parallel. 
55 
normocholesterolemic 
volunteers. 
3 capsules of synbiotics 
product (consisted of  
10
9 CFU/g of L. 
acidophilus & B. 
longum, & 10-15 mg of 
FOS) once daily for 2 
months. 
No significant 
improvement 
in lipid 
profiles. 
[65] 
TC: Total cholesterol; LDL-C: Low-density lipoprotein cholesterol. 
Such controversial findings may be attributed to various factors. Although in vivo trials utilize real 
life models with true representations of the actual pathological systems, these trials are also easily 
affected by external factors such as different strains of probiotics, varying types of prebiotics, 
administration dosage, analytical accuracy of lipid analyses, clinical characteristic of subjects, duration 
of treatment period, inadequate sample sizes, and lack of suitable controls or placebo groups [65,66]. Int. J. Mol. Sci. 2010, 11               
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Although some of these studies failed to yield significant results, the reported hypocholesterolemic 
potential of probiotics and prebiotics supplementation warrants further research.  
3. Dosage-Response Effects 
Although the hypocholesterolemic potential of probiotics and prebiotics has been widely studied, an 
accurate dosage of administration has yet to be established. There is a lack of dosage-response studies 
to determine the ‘minimal effective dosage’ of probiotics and/or prebiotics needed to reduce blood 
cholesterol levels. The concentration of probiotics in food products varies tremendously and there are 
currently no regulated standards for probiotic products to produce a cholesterol-lowering effect [67]. A 
review of past studies has revealed that the effective administration dosages of probiotics vary greatly 
and is dependent on the strains used and the clinical characteristics of subjects, such as lipid profiles. 
Although probiotics have been delivered in the range of 10
7 to 10
11 CFU/day in humans [68] and 10
7 to 
10
9 CFU/day in animals [69,70], some probiotics have been shown to be efficacious at lower levels, 
while some require a substantially higher amount to exert a hypocholesterolemic effect.  
The administration of L. plantarum 299 v at a dosage of 5.0 × 10
7 CFU/mL daily has been found 
sufficient to reduce LDL-cholesterol by 12% compared to the control [68]. In contrast, the 
consumption of probiotic capsules containing Lactobacillus acidophilus DDS-1 and Bifidobacterium 
longum (3  10
9 CFU/capsule daily) did not produce significant changes in lipid profiles [71]. This 
suggests that higher dosage may not necessarily translate to better effects on cholesterol, as compared 
to lower dosage. Different strains need varying dosage to exhibit hypocholesterolemic effects   
(Table 2). Clinically effective dosage of probiotics should only be established based on studies of the 
specific strains conducted in humans.  
Table 2. Dosage-response effects of different probiotic strains on lipid profiles. 
Products/ 
Probiotic 
strains 
Experimenta
l design 
Animals/Subjects 
Dose; 
duration of 
the study 
Effects  Ref. 
    Animal models       
L. plantarum 
CK 102 
(healthy 
human isolate) 
Randomized, 
placebo-
controlled, 
parallel.  
32 Sprague-Dawley 
(SD) male rats;  
5 weeks old; induced 
hypercholesterolemic; 
mean BW of  
129 ± 1 g. 
5.0 × 10
7 
CFU/mL 
daily, 6 
weeks. 
TC: 27.9% decrease  
(P < 0.05)  
LDL-C: 28.7% 
decrease (P < 0.05)  
TG: 61.6% decrease 
(P < 0.05)  
[70] 
L. acidophilus 
(wild chickens 
& human 
isolates) 
Randomized, 
placebo-
controlled, 
parallel.  
30 Awassi weaning 
lambs; 
hypercholesterolemic
; mean BW of  
55.1 ± 3.4 &  
57.9 ± 4.7 kg for the 
treated & control 
groups, respectively. 
1 × 10
9 
CFU/capsule
,  
2 capsules 
daily, 120 
days. 
TC: 22.6% decrease 
(P < 0.05)  
[treatment group with 
mean plasma TC of 
72.8 ± 5.7 mg/100 mL; 
control group with 
mean plasma TC of 
94.0 ± 7.8 mg/100 mL] 
[69] Int. J. Mol. Sci. 2010, 11               
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Table 2. Cont. 
Products/ 
Probiotic 
strains 
Experimen
tal design 
Animals/Subjects 
Dose; 
duration of 
the study 
Effects  Ref. 
    Animal models       
L. plantarum 
KCTC3928 
(Cellbiotech 
Co. Ltd, 
Korea) 
Randomize
d, placebo-
controlled, 
parallel.  
21 six-week-old 
C57BL/6 male 
mice; induced 
hypercholesterolemic. 
1 × 10
9
CFU/mL of L. 
plantarum 
KCTC3928,  
4 weeks. 
TC: 33% decrease  
(P < 0.05)  
LDL-C: 42% decrease 
(P < 0.05)  
TG: 32% decrease  
(P < 0.05)  
HDL-C: 35% increase 
(P < 0.05)  
[72] 
Human models 
L. plantarum 
299v 
(ProViva) 
Randomize
d, placebo-
controlled, 
double-
blind, 
parallel.  
36 healthy 
volunteers with 
moderately elevated 
fibrinogen 
concentrations  
(>3.0 g/L);  
35-45 years old; 
mean TC of  
5.59 ± 0.88 mmol/L 
for treatment group 
& 5.51 ± 0.75 mmol/L 
for control group. 
400 mL of 
rose-hip drink 
containing  
5.0 × 10
7 
CFU/mL daily, 
6 weeks. 
TC: 2.5% decrease  
LDL-C: 7.9% 
decrease  
[68] 
Enterococcus 
faecium & 2 
strains of 
Streptococcus 
thermophilus 
(Causido®; 
Gaio®) 
Randomize
d, placebo 
controlled, 
double-
blind, 
crossover.  
32 patients;  
36-65 years old; 
mean TC of  
248.47 ± 26.75 mg/dL, 
mean LDL-C of 
172.22 ± 21.17 mg/dL. 
200 g of Gaio® 
containing  
10
5-10
9 /mL of 
E. faecium &  
5-20 × 10
8/mL of 
S. thermophilus 
daily, 16 weeks. 
TC: 5.3% decrease (P 
= 0.004)  
LDL-C: 6.15% 
decrease  
(P = 0.012)  
 
[73] 
TC: Total cholesterol; LDL-C: Low-density lipoprotein cholesterol; HDL-C: High-density 
lipoprotein cholesterol; TG: triglycerides; BW: body weight. 
 
Similar to probiotics, there is also no recommended daily dosage of prebiotics that specifically exert 
a hypocholesterolemic effect [74]. Past studies have demonstrated the efficiency of various prebiotics 
and the combination of prebiotics and oligosaccharides in different dosages. While one study 
demonstrated the efficacy of lactulose and L-rhamnose in reducing fasting triglycerides, at dosages of 
15 g/day and 25 g/day respectively [75], another study showed that arabinogalactan administered in 
dosages up to 30 g/day produced insignificant effect on lipid profiles [76]. It appears that the 
hypocholesterolemic effect is specific to the different types of prebiotics (Table 3). These inconsistent 
findings call for more in-depth studies to ascertain the proper dosage of prebiotics specifically 
targeting a hypocholesterolemic effect.  Int. J. Mol. Sci. 2010, 11               
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Table 3. Dosage-response effects of different prebiotics/oligosaccharides on lipid profiles. 
Prebiotics/ 
Oligosaccharides 
Experimental 
design 
Animals/ 
Subjects 
Dose; 
duration of 
the study 
Effects  Ref. 
Animal Models 
Inulin  Randomized, 
placebo-
controlled, 
parallel.  
10 male golden Syrian 
hamsters, mean BW 
of  
58 ± 4 g. 
16% of inulin 
daily, 5 weeks. 
TC: 29% decrease 
(P < 0.05)  
TG: 63% decrease 
(P < 0.05) 
[77] 
Chito-
oligosaccharides 
(COS) 
Randomized, 
placebo-
controlled, 
parallel.  
49 male Arbor Acres 
broiler chickens;  
196 days old. 
100 mg/kg BW 
daily, 42 days. 
TG: 26.9% 
decrease (P < 0.05)  
HDL-C: 12.3% 
increase (P < 0.05)  
[78] 
Xylo-
oligosaccharides 
(XOS) 
Randomized, 
placebo-
controlled, 
parallel.  
40 male Sprague-
Dawley rats;  
6 weeks old.  
60 g XOS/kg 
diet, 35 days. 
TG: 33.9% 
decrease (P < 0.05) 
[79] 
Soybean 
oligosaccharides 
Randomized, 
placebo-
controlled, 
parallel.  
50 Wistar rats; aged 
of 4-week; induced 
hypercholesterolemic. 
450 mg/kg BW 
/day, 45 days. 
TC: 38.5% 
decrease (P < 0.05) 
LDL-C: 43.0% 
decrease (P < 0.05)  
TG: 40.8% 
decrease (P < 0.05) 
HDL-C: 81.9% 
increase (P < 0.05)  
(compared to the 
positive control 
group) 
[80] 
Human Models 
Inulin  Randomized, 
placebo-
controlled, 
double-blind, 
crossover.  
8 healthy volunteers; 
23-32 years old, BMI 
of 19-25 kgm
-2.  
10 g/day, 3 
weeks.  
TG: 16.3% 
decrease (P < 0.05) 
[50] 
Fructo-
oligosaccharides 
(FOS) 
Randomized, 
placebo-
controlled, 
single-blind, 
crossover.  
20 diabetic & 
hypercholesterolemic 
volunteers with fasting 
serum TC 
concentrations  
> 6 mmol/L. 
15 g/day, two  
20 days 
treatment period, 
no washout 
period between 
treatments. 
HDL-C: 2.8% 
increase  
[81] 
Galacto-
oligosaccharides 
Randomized, 
placebo-
controlled, 
double-blind, 
crossover.  
44 elderly volunteers  
(16 men & 28 
women);  
64-79 years old. 
5.5 g/d, two 10 
weeks treatment 
period, 4-week 
washout period. 
No significant 
improvement in 
lipid profiles. 
[82] 
TC: Total cholesterol; LDL-C: Low-density lipoprotein cholesterol; HDL-C: High-density 
lipoprotein cholesterol; TG: triglycerides; BMI: Body Mass Index; BW: body weight. Int. J. Mol. Sci. 2010, 11               
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Several studies have also been conducted to determine and justify the use of various formulations of 
synbiotics for cholesterol-lowering effect. Researchers have optimized cholesterol removal by 
synbiotics in laboratory media. Using response surface methodology (RSM), Liong and Shah [83] 
demonstrated that L. casei ASCC 292 reduced the highest amounts of cholesterol in vitro in the 
presence of fructooligosaccharides (FOS) and maltodextrin. The greatest reduction of cholesterol was 
observed from the combination of 1.71% (w/v) L. casei ASCC 292, 4.95% (w/v) FOS and 6.64% 
(w/v) maltodextrin. This optimized formulation was further explored in rats [29]. In a 6-week study 
using twenty-four hypercholesterolemic male Wistar rats, daily oral-administration of the synbiotic 
product demonstrated promising hypocholesterolemic effects [29]. Rats fed with the synbiotic product 
(L. casei at 10
9 CFU/g) showed a significantly (P < 0.05) lower total cholesterol and triglyceride 
(16.7% and 27.1% lower, respectively) compared to the control. However, when rats were fed with the 
diet comprising of L. casei and individual FOS or maltodextrin, insignificant difference in lipid 
profiles was observed. These findings illustrated the different stimulative effects of different prebiotics 
on probiotics, leading to different hypocholesterolemic outcomes. In another study, Zhang et al. [84] 
optimized the production of a synbiotic for in vitro cholesterol removal. The authors also utilized RSM 
and involved L. plantarum LS12 as the probiotic, and galactooligosaccharides (GOS) and mannitol as 
the prebiotics. The authors observed that L. plantarum LS12 in the presence of GOS and mannitol 
could reduce 75.9% more cholesterol compared to the control (glucose-supplemented medium).  
Thus, more studies are needed, not only to determine the effective dosage of synbiotic to exhibit 
hypocholesterolemic effects, but also to evaluate the effects of symbiosis between probiotics and 
prebiotics on cholesterol-lowering/removing properties. It is subjective to state a general dosage that 
could be applied to all probiotic/prebiotic products to exhibit a hypocholesterolemic effect. The 
prescribed dosage should also be justified by well-designed in vivo studies specifically investigating 
on cholesterol profiles. 
4. Mechanisms of Cholesterol-Lowering Effects  
Past in vitro studies have evaluated a number of mechanisms proposed for the cholesterol-lowering 
effects of probiotics and prebiotics. One of the purported mechanisms includes enzymatic 
deconjugation of bile acids by bile-salt hydrolase of probiotics. Bile, a water-soluble end product of 
cholesterol in the liver, is stored and concentrated in the gallbladder, and released into the duodenum 
upon ingestion of food [85]. It consists of cholesterol, phospholipids, conjugated bile acids, bile 
pigments and electrolytes. Once deconjugated, bile acids are less soluble and absorbed by the 
intestines, leading to their elimination in the feces. Cholesterol is used to synthesize new bile acids in a 
homeostatic response, resulting in lowering of serum cholesterol [85] (Figure 1). In an in vitro study, 
Jones et al. [86] evaluated the role of bile salt hydrolase in cholesterol-lowering using Lactobacillus 
plantarum 80 (pCBH1). Bile salt hydrolase (BSH) is the enzyme responsible for bile salt 
deconjugation in the enterohepatic circulation. It has been detected in probiotics indigenous to the 
gastrointestinal tract. The authors found that BSH activity was able to hydrolyze conjugated 
glycodeoxycholic acid and taurodeoxycholic acid, leading to the deconjugation of glyco- and   
tauro-bile acids.  Int. J. Mol. Sci. 2010, 11               
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Figure 1. Cholesterol as the precursor for the synthesis of new bile acids and the 
hypocholesterolemic role of bile salt hydrolase. 
 
 
The hypocholesterolemic effect of the probiotics has also been attributed to their ability to bind 
cholesterol in the small intestines (Figure 2). Usman and Hosono [87] previously reported that strains 
of Lactobacillus gasseri could remove cholesterol from laboratory media via binding onto cellular 
surfaces. The ability of cholesterol-binding appeared to be growth and strain specific. Kimoto et al. 
[88] later strengthened such a hypothesis by evaluating the removal of cholesterol by probiotics cells 
during different growth conditions. Live and growing cells were compared to those that were non-
growing (live but suspended in phosphate buffer) and dead (heat-killed). The authors found that 
although growing cells removed more cholesterol than dead cells, the heat-killed cells could still 
remove cholesterol from media, indicating that some cholesterol was bound to the cellular surface.  
Figure 2. Scanning electron micrograph of Lactobacillus bulgaricus cultivated in   
(A) media without cholesterol and (B) broth supplemented with cholesterol (100 mM). 
(A)         (B) 
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Cholesterol was also removed by probiotics by incorporation into the cellular membranes during 
growth. Kimoto et al. [88] has examined the removal of cholesterol by several strains of lactococci 
from media. The authors observed a difference in the fatty acid distribution pattern for cells grown in 
the presence and absence of cholesterol. Lipids of probiotics are predominantly found in the 
membrane, suggesting that cholesterol incorporated into the cellular membrane had altered the fatty 
acid composition of the cells. The incorporation of cholesterol into the cellular membrane increased 
the concentration of saturated and unsaturated fatty acids, leading to increased membrane strength and 
subsequently higher cellular resistance toward lysis [31]. Lye et al. [31] also further evaluated this 
mechanism by determining the possible locations of the incorporated cholesterol within the membrane 
phospholipid bilayer of probiotic cells. The authors incorporated fluorescence probes into the 
membrane bilayer of probiotic cells that were grown in the absence and presence of cholesterol. 
Enrichment of cholesterol was found in the regions of the phospholipid tails, upper phospholipids, and 
polar heads of the cellular membrane phospholipid bilayer in cells that were grown in the presence of 
cholesterol compared to the control cells, indicating incorporation of cholesterol in those regions.  
Cholesterol can also be converted in the intestines to coprostanol, which is directly excreted in 
feces. This decreases the amount of cholesterol being absorbed, leading to a reduced concentration in 
the physiological cholesterol pool. Possible conversion of cholesterol into coprostanol by bacteria has 
been evaluated by Chiang et al. [89]. In their study, the authors found that cholesterol 
dehydrogenase/isomerase produced by bacteria such as Sterolibacterium denitrificans was responsible 
for catalyzing the transformation of cholesterol to cholest-4-en-3-one, an intermediate cofactor in the 
conversion of cholesterol to coprostanol. This served as a fundamental for further evaluations using 
strains of probiotic bacteria. In a recent in vitro study, Lye et al. [32] evaluated the conversion of 
cholesterol to coprostanol by strains of lactobacilli such as Lactobacillus acidophilus, L. bulgaricus 
and  L. casei ATCC 393 via fluorometric assays. The authors detected both intracellular and 
extracellular cholesterol reductase in all strains of probiotics examined, indicating possible 
intracellular and extracellular conversion of cholesterol to coprostanol. The concentration of 
cholesterol in the medium also decreased upon fermentation by probiotics accompanied by increased 
concentrations of coprostanol. This mechanism warrants further evaluations as cholesterol reductase is 
also directly administered to humans to convert cholesterol to coprostanol in the small intestines for a 
bloodstream cholesterol-lowering effect.  
Most of the hypotheses raised to date are based on in vitro experiments, and few attempts have been 
made to evaluate the possible hypocholesterolemic mechanisms based on in vivo trials. Most of the in 
vivo trials conducted thus far have focused heavily on verifying the hypocholesterolemic effects of 
probiotics, rather than the mechanisms involved. Liong et al. [56] had evaluated the 
hypocholesterolemic effect of a synbiotic and the possible mechanisms involved by using 24 crossbred 
(Large White × Landrace) hypercholesterolemic pigs. In their parallel 8-week study, the authors found 
that the administration of a synbiotic containing L. acidophilus ATCC 4962, fructooligosaccharides, 
inulin and mannitol decreased plasma total cholesterol, LDL-cholesterol and triacylglycerols 
compared to the control. These lipoproteins were subsequently subfractionated and characterized. Pigs 
supplemented with the synbiotic had a lower concentration of cholesteryl esters in the LDL particles, 
accompanied by a higher concentration of triacylglycerol. Triacylglycerol-enriched LDL particles are 
more susceptible to hydrolysis and removal from blood, while loss of cholesteryl esters forms smaller Int. J. Mol. Sci. 2010, 11               
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and denser LDL particles leading to a higher removal from blood compared to larger LDL particles. 
The authors also found that the administration of the synbiotic led to higher concentration of 
cholesteryl esters in the HDL particles. HDL is termed as the beneficial cholesterol attributed to its 
role of transporting cholesterol to the liver for further hydrolysis. Cholesterol is transported as 
cholesteryl esters in the core of HDL. Thus, the authors suggested that the synbiotic induced a 
hypocholesterolemic effect via altering the pathways of cholesteryl esters and lipoprotein transporters.  
Prebiotics such as inulin and fructooligosaccharides are soluble, indigestible, viscous and 
fermentable compounds that contribute to hypocholesterolemia via two mechanisms: decreasing 
cholesterol absorption accompanied by enhanced cholesterol excretion via feces, and the production of 
short-chain fatty acids (SCFAs) upon selective fermentation by intestinal bacterial microflora [90]. 
Using Sprague-Dawley hypercholesterolemic-induced rats (n = 32), Kim and Shin [91] found that the 
administration of inulin for 4-weeks decreased serum LDL-cholesterol with increased serum HDL-
cholesterol levels (P < 0.05) compared to the control. Rats fed with inulin also showed higher 
excretions of fecal lipid and cholesterol compared to the control (P < 0.05), mainly attributed to 
reduced cholesterol absorption. Similar to indigestible fibers, soluble indigestible prebiotics have been 
postulated to increase the viscosity of the digestive tract and increase the thickness of the unstirred 
layer in the small intestine, and thus inhibiting the uptake of cholesterol [92]. This may have led to a 
higher cholesterol catabolism in the liver that contributed to a hypocholesterolemic effect.  
Prebiotics are fermented in the colon by large bowel bacteria, yielding short-chain fatty acids 
(SCFAs) such as butyrate, acetate and propionate. Fermentation of prebiotics involves a variety of 
metabolic processes in the anaerobic microbial breakdown of organic compounds, yielding energy for 
microbial growth and the production of SCFAs [79]. Rossi et al. [93] found that butyrate was the 
major fermentation product from inulin, whereas acetate was produced from fructooligosaccharides. 
The hypocholesterolemic effect of prebiotics has been mainly attributed to SCFAs. Butyrate is known 
to inhibit liver cholesterol synthesis and provide a source of energy for human colon epithelial cells, 
meanwhile propionate may inhibit the synthesis of fatty acids in the liver, thereby lowering the rates of 
triacylglycerol secretion [77]. Propionate is also involved in the control of hepatic cholesterol 
synthesis and it reduces the rate of cholesterol synthesis which could lead to the lowering of plasma 
cholesterol levels [77].  
In conclusion, the mechanisms proposed for mediating hypocholesterolemic effect by probiotics 
and/or prebiotics are numerous. Although those hypotheses were proved via in vitro studies, the 
mechanisms are not firmly established and demonstrated in in vivo studies. Therefore, more in vivo 
studies are needed to explore the underlying mechanism of cholesterol-lowering effects by probiotics 
and/or prebiotics in order to have a better understanding of the mechanisms and better formulations for 
human consumption. 
5. Safety of Probiotics and Prebiotics 
The current use of probiotics does not require approval from the FDA. Although most members of 
lactobacilli and bifidobacteria are safe for consumption, some species such as L. rhamnosus, L. casei, 
L. paracasei, L. leichmannii, L. confuses and L. plantarum have been isolated from infectious sites. 
Lactobacilli are generally known as the normal microflora in the gastrointestinal tract; however, cases Int. J. Mol. Sci. 2010, 11               
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such as septicaemia, bacteremia [94-96] and endocarditis [97]
 have been recorded, inflicting infants, 
elderly and the immune-compromised [98]. These cases are uncommon and many studies have proven 
that probiotics
 were not the contributory mediator and these cases were usually prompted by individual 
underlying diseases. Some adverse effects might be induced by probiotics, some of which have been 
documented in the literature, including systemic infections (Table 4), deleterious metabolic activities, 
possible genetic interactions between probiotics and intestinal microbes and occurrence of antibiotic 
resistance in probiotics. These cases of adverse effects were often accompanied by other disease, 
occurrence of gastrointestinal inflammation and lesions, or by an impaired immune system. 
Table 4. Isolation of lactobacilli from clinical cases of systemic infections. 
Patient’s 
age 
(year)/sex 
Diagnosis 
Underlying 
condition (s) 
Organism 
(s) isolated 
Therapy; 
duration of 
the therapy 
Outcome  Ref. 
46/M  Bacteremia  Short-bowel 
syndrome, history of 
Enterococcus faecalis 
aortic valve 
endocarditis, 
Klebsiella pneumonia 
bacteremia & 
candidemia. 
L. confuses; 
isolated from 
blood culture. 
Piperacillin-
tazobactam & 
gentamicin, 4 
weeks. 
Recovered.  [94] 
21/F  Bacteremia  Fever, drownsiness & 
stiff neck. 
L. helvetica; 
isolated from 
blood culture. 
Amoxicillin & 
gentamicin,  
10 days; 
clindamycin,  
15 days. 
Recovered  [95] 
59/F  Bacteremia  Hypertension, 
diabetes mellitus type 
2, history of breast 
cancer with 
conservative surgery 
& kidney stone. 
L. jensenii; 
isolated from 
blood & urine 
culture. 
Ampicillin,  
2 weeks. 
Recovered  [96] 
53/M  Endocarditis  History of rheumatic 
fever. 
L. casei; 
isolated from 
the blood & 
bone marrow. 
Valve 
replacement 
surgery and was 
treated with 
doxycycline. 
Recovered  [97] 
74/F  Liver abscess  Hypertension, non-
insulin-dependent 
diabetes mellitus & 
pneumonia. 
L. rhamnosus; 
isolated from 
blood culture. 
Ciprofloxacin & 
clindamycin,  
6 weeks. 
Recovered  [98] 
 
The deleterious metabolic activities of probiotics such as mucin degradation and translocation 
contribute to possible adverse effects upon the consumption. Following the ingestion of probiotics in 
the gastrointestinal tract, the load of microorganisms passing through the small bowel is increased, Int. J. Mol. Sci. 2010, 11               
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which could cause gastrointestinal disturbances including intestinal inflammation. It has been 
hypothesized that the accumulation of probiotics along the gastrointestinal tract might lead to the risk 
of intestinal mucus degradation. However, current findings do not support such a suggestion. Ruseler-
van Embden et al. [99] determined the mucus glycoprotein degradation ability of Lactobacillus casei 
strain GG, Lactobacillus acidophilus,  Bifidobacterium bifidum and a mesophylic lactic culture 
(isolated from a commercial fermented product) in germ-free rats. The authors reported that the 
probiotics strains tested did not degrade intestinal mucus glycoproteins and no damage was observed 
on the intestinal mucus layer. Recently, Abe et al. [100] evaluated Bifidobacterium longum BB536, 
Bifidobacterium breve M-16V and Bifidobacterium infantis M-63 on mucin degradation activity in 
vitro. No mucin degradation activity was observed and the authors further explored the translocation 
ability of Bifidobacterium longum BB536 in ten 4-weeks-old mice. No translocation was detected and 
no damage was observed on epithelial cells or to the mucosal layer in the ileum, cecum and colon.  
The production of bile salt hydrolase (BSH) by probiotic strains could increase the accumulation of 
deconjugated bile which could be subsequently transformed into detrimental secondary bile acids by 
intestinal microflora. It has been suggested that the accumulation of potentially cytotoxic secondary 
bile acids in the enterohepatic circulation could increase the risk of gastrointestinal diseases such as 
cholestasis and colorectal cancer [101]. Little information is available on such a possibility and to our 
knowledge, there has been no study that specifically evaluates the detrimental effects of BSH from 
probiotics on humans. More studies are needed to ascertain that the deleterious effects of BSH from 
probiotics do not outweigh its benefits.  
Adverse immunological effects have been postulated to occur as a result of administration routes, 
which included oral or parental administration. When probiotics are administered parentally, their cell 
walls containing peptidoglycan polysaccharides has been postulated to cause adverse effects such as 
fever, arthritis, cardioangitis, hepatobiliary lesions or autoimmune diseases [102]. Although it has been 
noted that these effects are mediated by different cytokines, the detailed mechanisms involved have 
not been substantially understood. Such a claim remains a hypothesis as there is no direct evidence 
supported by in vivo trials, and warrants further investigation. 
The adverse effect in terms of genetic interactions between ingested probiotics and the native 
intestinal microbes has also been a topic of interest. The phenomenon whereby genetic materials 
represented by plasmids are transferred between microorganisms in our body [103] raises the question 
of whether genetic exchange may occur between probiotics and the microorganisms in the 
gastrointestinal tract. Transduction, conjugation and transformation have been identified as the three 
basic forms of microbial genetic exchange within gut microbial communities [104-106]. It has been 
suggested that the transformation of intestinal microflora by DNA may be enhanced upon ingestion of 
bacteria, leading to genetic rearrangements in the pool of gastrointestinal microflora. The 
gastrointestinal tract is populated by a complex microflora colony. It could act as a pool for the 
transmission of antibiotic-resistance genes among beneficial bacteria and harmful pathogens. This 
transmission can consequently lead to the evolution of antibiotic-resistant probiotics [107] and 
potential emergence of resistant pathogens.  
D’Aimmo et al. [108] isolated 34 strains of Lactobacillus and Bifidobacterium and 21 strains of 
starter culture bacteria (such as Streptococcus thermophilus) from dairy products. The authors found 
that all strains tested were resistant to the antibiotics such as aztreonam, cycloserin, kanamycin, Int. J. Mol. Sci. 2010, 11               
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nalidixic acid, polymyxin B and spectinomycin. In another in vitro study, Hummel et al. [109] 
evaluated antibiotic resistant genes in 45 strains of probiotics from the genera of Lactobacillus, 
Streptococcus, Lactococcus, Pediococcus and Leuconostoc by using polymerase chain reaction (PCR). 
The authors found that 77.8 % of the probiotic strains examined were resistant to gentamicin, 
streptomycin and ciprofloxacin. A previous case study also reported such an occurrence in infants. A 
6-week-old infant was hospitalized for a scheduled repair of a double-outlet right ventricle and 
pulmonic stenosis, and had received a broad-spectrum of antibiotics including vancomycin and 
ceftriaxone. A probiotic supplement containing Lactobacillus rhamnosus GG was also introduced 
through the gastrostomy tube (10 × 10
9 cells/capsule; one capsule daily). The infant later developed 
onset fever and marked leukocytosis, and thus blood samples were drawn for culture examination. The 
blood culture isolates were positive for Lactobacillus species, which were resistant to vancomycin, 
meropenem, ceftriaxone and cefuroxime [35].  
Prebiotics such as inulin and oligofructose are present in our daily diet intake. Daily intake of inulin 
and oligofructose has been estimated at up to 10 g in the population of the United States [110]. The 
safety of inulin and oligofuctose for food application was evaluated by many legal authorities 
worldwide, and in vivo experimental evidence has not demonstrated any toxic effects [74]. However, 
prebiotics at very high doses might increase incidences of bloating, flatulence and high osmotic 
pressure which lead to gastrointestinal discomfort [111]. The effects might vary widely between 
individuals and depend on the type of food in which the prebiotics are incorporated.  
Prebiotics such as fructooligosaccharides (FOS) stimulate the growth of intestinal microflora and 
increasing organic acid concentrations within the lower part of gastrointestinal tract [79,93] which 
further contribute to health benefits such as cholesterol-lowering effect and enhancing the resistance to 
intestinal pathogens. However, some studies found that a high dose of FOS exhibited adverse effects in 
animal models. In a randomized, placebo-controlled and parallel designed study, Bruggencate et al. 
[112] administered 60 g/kg of FOS into ten specific pathogen–free 8-week-old male Wistar rats (with a 
mean body weight of 226 g) for 14 days. The rats were also infected with salmonella. FOS increased 
translocation of salmonella to extraintestinal sites, mucin excretion and cytotoxicity of fecal water in 
the FOS group compared to the control. FOS was found to impair the intestinal barrier in rats, as 
indicated by higher intestinal permeability. The authors further extrapolated their findings using 
humans as a model. In the double-blind, placebo-controlled, crossover designed study with a washout 
period of two weeks, Bruggencate et al. [113] studied the adverse effects of FOS in thirty-four men 
(aged 18-55 years old). In this study, the subjects consumed either lemonade with 20 g of FOS (purity 
93%, Raftilose P95, Orafti) or 6 g of sucrose (placebo) daily. The authors discovered that the 
consumption of FOS increased flatulence, intestinal bloating and fecal mucin excretion, indicating the 
occurrence of mucosal irritation. However, the authors found that FOS did not affect the cytotoxicity 
of fecal water and intestinal permeability, and the overall effects were more moderate than those in rats. 
It appears that high dosage of FOS can cause minor disturbances in the gastrointestinal tract, but such 
cases are far from being a risk to life [22]. 
On the whole, probiotics and prebiotics are safe for consumption due to their low ability of triggering 
adverse effects [5,67]. At this point, there is no standard analysis or assay suggested for safety assessment 
on probiotics and prebiotics [67]. However, each probiotic and prebiotic should be evaluated for safety, so Int. J. Mol. Sci. 2010, 11               
 
 
2515
that these strains can be isolated for specific purposes at specific dosages to prevent potential adverse 
reactions.  
6. Conclusions 
Probiotic and/or prebiotics have been widely assessed for their effects on lipid profiles such as total 
cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides. However, not all trials have yielded 
conclusive results. Certain strains of probiotic and types of prebiotic have demonstrated cholesterol-
lowering property while others did not. In order to justify the varying cholesterol-lowering effect 
exhibited by various strains of probiotics or types of prebiotics, researchers have endeavored to reveal 
the mechanisms of probiotics and/or prebiotics on hypocholesterolemic effect through in vitro and in 
vivo studies. Many of the proposed mechanisms and experimental evidence specifically targeting 
cholesterol-lowering effects remain controversial. Thus, more properly-designed in vivo trials may 
disclose additional understanding and knowledge to eliminate the controversies, to better understand 
the underlying mechanisms and for better safety assessment prior to consumption.  
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